Cart
sales@molnova.com
JNJ63576253
CAS No. 2110428-64-1
JNJ63576253( TRC-253 )
Catalog No. M23962 CAS No. 2110428-64-1
JNJ-63576253 is a Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 35 | In Stock |
|
| 5MG | 58 | In Stock |
|
| 10MG | 102 | In Stock |
|
| 25MG | 222 | In Stock |
|
| 50MG | 356 | In Stock |
|
| 100MG | 530 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameJNJ63576253
-
NoteResearch use only, not for human use.
-
Brief DescriptionJNJ-63576253 is a Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
-
DescriptionJNJ-63576253 is a Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC).
-
In Vitro——
-
In VivoAnimal Model:Castrated SHO mice with prostate LNCaP SRα F877L tumor Dosage:30 mg/kg Administration:P.o. once daily for 72 days Result:Inhibited the tumor growth by 87%.Animal Model:CD-1 male mice Dosage:2 mg/kg for i.v.; 10 mg/kg for p.o. (Pharmacokinetic Analysis)Administration:Intravenous administration and oral administration Result:I.v.: T1/2=5.99 h; CL=15.0 mL/min/kg; Vdss=6.11 L/kg.P.o.: F=45%; Cmax=0.66 μM; AUClast=4.9 μg?h/mL.
-
SynonymsTRC-253
-
PathwayEndocrinology/Hormones
-
TargetAndrogen Receptor (AR)
-
RecptorAndrogen Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2110428-64-1
-
Formula Weight538.97
-
Molecular FormulaC23H22ClF3N6O2S
-
Purity>98% (HPLC)
-
SolubilityDMSO: 200mg/mL?(371.08 mM);H2O: insoluble
-
SMILESN#CC1=NC=C(N(C2=O)C(N(C3=CC=C(OC4CCNCC4)N=C3)C52CCC5)=S)C=C1C(F)(F)F.[H]Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Zhang Z , Connolly P J , Lim H K , et al. Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)[J]. Journal of Medicinal Chemistry, 2021, 64(2).
molnova catalog
related products
-
BMS-564929
BMS-564929 is a potent, selective androgen receptor modulator (SARM) that binds to AR with Ki of 2.11 nM.
-
Nilutamide
Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate Y. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors).
-
Methandrostenolone
Methandienone is a synthetic steroid with anabolic properties that are more pronounced than its androgenic effects.
